Journal Home > Volume 2 , Issue 3-4
Food Science and Human Wellness 2013, 2(3-4): 167-172 https://doi.org/10.1016/j.fshw.2013.09.002
Review Article | Open Access | Issue | Published: 11 October 2013

Microbiota associated with type 2 diabetes and its related complications

Show Author's Information Yong Zhang,  Heping Zhang( )
Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Department of Food Science and Engineering, Inner Mongolia Agricultural University, Hohhot 010018, PR China

Peer review under responsibility of Beijing Academy of Food Sciences.

Keywords:
Microbiota, Type 2 diabetes, T2DM complications
Cite this article:
Zhang Y, Zhang H. Microbiota associated with type 2 diabetes and its related complications. Food Science and Human Wellness, 2013, 2(3-4): 167-172. https://doi.org/10.1016/j.fshw.2013.09.002
Download citation
EndNote(RIS)
BibTeX

320

Views

7

Downloads

Citations

81

Crossref

N/A

WoS

81

Scopus

0

CSCD

Abstract Full text About this article

Recently, it has been established that the human resident microbiota plays key roles in health maintenance. Therefore, it has become an emerging prevention and treatment target for metabolic syndrome. The resident microbiota associated with chronic inflammation has been shown to contribute to the onset of type 2 diabetes mellitus (T2DM). Moreover, the microbiota is altered in the development of T2DM and its comorbid medical conditions/diseases, including diabetic retinopathy, kidney toxicity, atherosclerosis, hypertension, diabetic foot ulcers, cycstic fibrosis and Alzheimer’s disease. Besides, some anti-T2DM regimens are also based microbiota metabolism-dependent mechanism. This review summarizes the current knowledge concerning the altered microbiota in the pathogenesis of T2DM and its related complications, which provides novel insights into these diseases and the potential intervention strategies from the microbiology point of view.


menu
Abstract
Full text
Outline
About this article

Microbiota associated with type 2 diabetes and its related complications

Show Author's information Yong Zhang, Heping Zhang( )
Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Department of Food Science and Engineering, Inner Mongolia Agricultural University, Hohhot 010018, PR China

Peer review under responsibility of Beijing Academy of Food Sciences.

Abstract

Recently, it has been established that the human resident microbiota plays key roles in health maintenance. Therefore, it has become an emerging prevention and treatment target for metabolic syndrome. The resident microbiota associated with chronic inflammation has been shown to contribute to the onset of type 2 diabetes mellitus (T2DM). Moreover, the microbiota is altered in the development of T2DM and its comorbid medical conditions/diseases, including diabetic retinopathy, kidney toxicity, atherosclerosis, hypertension, diabetic foot ulcers, cycstic fibrosis and Alzheimer’s disease. Besides, some anti-T2DM regimens are also based microbiota metabolism-dependent mechanism. This review summarizes the current knowledge concerning the altered microbiota in the pathogenesis of T2DM and its related complications, which provides novel insights into these diseases and the potential intervention strategies from the microbiology point of view.

Keywords: Microbiota, Type 2 diabetes, T2DM complications

References(81)

[1]

M.G. Gareau, P.M. Sherman, W.A. Walker, Probiotics and the gut microbiota in intestinal health and disease, Nature Reviews Gastroenterology & Hepatology 7 (2010) 503–514.
DOI Google Scholar
[2]

P.J. Turnbaugh, R.E. Ley, M.A. Mahowald, et al., An obesity-associated gut microbiome with increased capacity for energy harvest, Nature 444 (2006) 1027–1031.
DOI Google Scholar
[3]

J.L. Round, S.K. Mazmanian, The gut microbiota shapes intestinal immune responses during health and disease, Nature Reviews Immunology 9 (2009) 313–323.
DOI Google Scholar
[4]

M.A. McArdle, O.M. Finucane, R.M. Connaughton, et al., Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies, Frontiers in Endocrinology 4 (2013) 52.
DOI Google Scholar
[5]

J. Lee, Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 Diabetes, Archives of Pharmacal Research 36 (2013) 208–222.
DOI Google Scholar
[6]

H. Tilg, A. Kaser, Gut microbiome, obesity, and metabolic dysfunction, Journal of Clinical Investigation 121 (2011) 2126–2132.
DOI Google Scholar
[7]

V. Tremaroli, F. Bäckhed, Functional interactions between the gut microbiota and host metabolism, Nature 489 (2012) 242–249.
DOI Google Scholar
[8]

M. Diamant, E.E. Blaak, W.M. Vos de, Do nutrient–gut–microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obesity Reviews 12 (2011) 272–281.
DOI Google Scholar
[9]

A. Everard, P.D. Cani, Diabetes, obesity and gut microbiota, Best Practice & Research Clinical Gastroenterology 27 (2013) 73–83.
DOI Google Scholar
[10]

S. Devaraj, P. Hemarajata, J. Versalovic, The human gut microbiome and body metabolism: implications for obesity and diabetes, Clinical Chemistry 59 (2013) 617–628.
DOI Google Scholar
[11]

X. Wu, C. Ma, L. Han, et al., Molecular characterisation of the faecal microbiota in patients with type Ⅱ diabetes, Current Microbiology 61 (2010) 69–78.
DOI Google Scholar
[12]

N. Larsen, F.K. Vogensen, F.W. van den Berg, et al., Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults, PLoS One 5 (2010) e9085.
DOI Google Scholar
[13]

J. Qin, Y. Li, Z. Cai, et al., A metagenome-wide association study of gut microbiota in type 2 diabetes, Nature 490 (2012) 55–60.
DOI Google Scholar
[14]

J. Romano-Keeler, J.H. Weitkamp, D.J. Moore, Regulatory properties of the intestinal microbiome effecting the development and treatment of diabetes, Current Opinion in Endocrinology, Diabetes and Obesity 19 (2012) 73–80.
DOI Google Scholar
[15]

R.S. Kootte, A. Vrieze, F. Holleman, et al., The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus, Diabetes, Obesity and Metabolism 14 (2012) 112–120.
DOI Google Scholar
[16]

N.M. Delzenne, P.D. Cani, Gut microbiota and the pathogenesis of insulin resistance, Current Diabetes Reports 11 (2011) 154–159.
DOI Google Scholar
[17]

A.P. Liou, M. Paziuk, J.M. Luevano, et al., Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity, Science Translational Medicine 5 (2013) 178ra41.
DOI Google Scholar
[18]

H. Panwar, H.M. Rashmi, V.K. Batish, et al., Probiotics as potential biotherapeutics in the management of type 2 diabetes – prospects and perspectives, Diabetes/Metabolism Research and Reviews 29 (2013) 103–112.
DOI Google Scholar
[19]

C.N. Lumeng, A.R. Saltiel, Inflammatory links between obesity and metabolic disease, Journal of Clinical Investigation 121 (2011) 2111–2117.
DOI Google Scholar
[20]

M.Y. Donath, Inflammation as a sensor of metabolic stress in obesity and type 2 diabetes, Endocrinology 152 (2011) 4005–4006.
DOI Google Scholar
[21]

N. Ouchi, J.L. Parker, J.J. Lugus, et al., Adipokines in inflammation and metabolic disease, Nature Reviews Immunology 11 (2011) 85–97.
DOI Google Scholar
[22]

T. Matsuzaki, R. Yamazaki, S. Hashimoto, et al., Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice, Endocrine Journal 44 (1997) 357–365.
DOI Google Scholar
[23]

F. Calcinaro, S. Dionisi, M. Marinaro, et al., Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse, Diabetologia 48 (2005) 1565–1575.
DOI Google Scholar
[24]

J.J. Chen, R. Wang, X. Li, Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression, Experimental Biology and Medicine 236 (2011) 823–831.
DOI Google Scholar
[25]

F.C. Hsieh, C.L. Lee, C.Y. Chai, et al., Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats, Nutrition & Metabolism 10 (2013) 35.
DOI Google Scholar
[26]

Z. Asemi, M. Samimi, Z. Tabassi, et al., Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial, European Journal of Clinical Nutrition 67 (2013) 71–74.
DOI Google Scholar
[27]

Z. Asemi, S. Jazayeri, M. Najafi, et al., Effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women: a randomized controlled trial, Pakistan Journal of Biological Sciences 14 (2011) 476–482.
DOI Google Scholar
[28]

H.S. Ejtahed, J. Mohtadi-Nia, A. Homayouni-Rad, et al., Probiotic yogurt improves antioxidant status in type 2 diabetic patients, Nutrition 28 (2012) 539–543.
DOI Google Scholar
[29]

Z. Asemi, S. Jazayeri, M. Najafi, et al., Effect of daily consumption of probiotic yogurt on oxidative stress in pregnant women: a randomized controlled clinical trial, Annals of Nutrition and Metabolism 60 (2012) 62–68.
DOI Google Scholar
[30]

L.G. Ooi, M.T. Liong, Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings, International Journal of Molecular Sciences 11 (2010) 2499–2522.
DOI Google Scholar
[31]

E. Naito, Y. Yoshida, K. Makino, et al., Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice, Journal of Applied Microbiology 110 (2011) 650–657.
DOI Google Scholar
[32]

J. Amar, C. Chabo, A. Waget, Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment, EMBO Molecular Medicine 3 (2011) 559–572.
DOI Google Scholar
[33]

Y. Zhang, L. Wang, J. Zhang, et al., Probiotic Lactobacillus casei Zhang ameliorates high-fructose-induced impaired glucose tolerance in hyperinsulinemia rats, European Journal of Nutrition (2013) (in press).
DOI Google Scholar
[34]

D.S. Fong, L. Aiello, T.W. Gardner, Retinopathy in diabetes, Diabetes Care 27 (2004) 84–87.
DOI Google Scholar
[35]

E.N. Martins, L.S. Alvarenga, A.L. Höfling-Lima, et al., Aerobic bacterial conjunctival flora in diabetic patients, Cornea 23 (2004) 136–142.
DOI Google Scholar
[36]

D. Karimsab, S.K. Razak, Study of aerobic bacterial conjunctival flora in patients with diabetes mellitus, Nepalese Journal of Ophthalmology 5 (2012) 28–32.
DOI Google Scholar
[37]

H. Bilen, O. Ates, N. Astam, et al., Conjunctival flora in patients with type 1 or type 2 diabetes mellitus, Advances in Therapy 24 (2007) 1028–1035.
DOI Google Scholar
[38]

E. Cereda, M. Barichella, C. Pedrolli, et al., Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis, Diabetes Care 34 (2011) 2614–2623.
DOI Google Scholar
[39]

T. Kusbeci, O.Y. Kusbeci, O.C. Aktepe, et al., Conjunctival flora in patients with Parkinson’s disease, Current Eye Research 34 (2009) 251–256.
DOI Google Scholar
[40]

N.D. Vaziri, J. Wong, M. Pahl, et al., Chronic kidney disease alters intestinal microbial flora, Kidney International 83 (2013) 308–315.
DOI Google Scholar
[41]

X. Zheng, A. Zhao, G. Xie, et al., Melamine-induced renal toxicity is mediated by the gut microbiota, Science Translational Medicine 5 (2013) 172ra22.
DOI Google Scholar
[42]

S.H. Duncan, A.J. Richardson, P. Kaul, et al., Oxalobacter formigenes and its potential role in human health, Applied and Environmental Microbiology 68 (2002) 3841–3847.
DOI Google Scholar
[43]

S. Turroni, B. Vitali, C. Bendazzoli, et al., Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus, Journal of Applied Microbiology 103 (2007) 1600–1609.
DOI Google Scholar
[44]

L. Borghi, A. Nouvenne, T. Meschi, Probiotics and dietary manipulations in calcium oxalate nephrolithiasis: two sides of the same coin? Kidney International 78 (2010) 1063–1065.
DOI Google Scholar
[45]

D.W. Stafford, The vitamin K cycle, Journal of Thrombosis and Haemostasis 3 (2005) 1873–1878.
DOI Google Scholar
[46]

B. Hu, T. Wang, Z. Liu, et al., Decreased expression of vitamin K epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis, Journal of Huazhong University of Science and Technology 31 (2011) 807–814.
DOI Google Scholar
[47]

J.L. Pluznick, R.J. Protzko, H. Gevorgyan, et al., Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation, Proceedings of the National Academy of Sciences of the United States of America 110 (2013) 4410–4415.
DOI Google Scholar
[48]

M. Tanida, T. Yamano, K. Maeda, et al., Effects of intraduodenal injection of Lactobacillus johnsonii La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats, Neuroscience Letters 389 (2005) 109–114.
DOI Google Scholar
[49]

T. Yamano, M. Tanida, A. Niijima, et al., Effects of the probiotic strain Lactobacillus johnsonii strain La1 on autonomic nerves and blood glucose in rats, Life Sciences 79 (2006) 1963–1967.
DOI Google Scholar
[50]

O. Koren, A. Spor, J. Felin, et al., Human oral, gut, and plaque microbiota in patients with atherosclerosis, Proceedings of the National Academy of Sciences of the United States of America 108 (2011) 4592–4598.
DOI Google Scholar
[51]

C. Moroti, L.F. Souza Magri, M. de Rezende Costa, et al., Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus, Lipids in Health and Disease 11 (2012) 29.
DOI Google Scholar
[52]

C.E. Milla, J. Billings, A. Moran, Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis, Diabetes Care 28 (2005) 2141–2144.
DOI Google Scholar
[53]

F. Harrison, Microbial ecology of the cystic fibrosis lung, Microbiology 153 (2007) 917–923.
DOI Google Scholar
[54]

A.F. Goddard, B.J. Staudinger, S.E. Dowd, et al., Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota, Proceedings of the National Academy of Sciences of the United States of America 109 (2012) 13769–13774.
DOI Google Scholar
[55]

J.C. Madan, D.C. Koestler, B.A. Stanton, et al., Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures, mBio 3 (2012) e00251.
DOI Google Scholar
[56]

E. Bruzzese, V. Raia, G. Gaudiello, et al., Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration, Alimentary Pharmacology & Therapeutics 20 (2004) 813–819.
DOI Google Scholar
[57]

B. Weiss, Y. Bujanover, Y. Yahav, et al., Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study, Pediatric Pulmonology 45 (2010) 536–540.
DOI Google Scholar
[58]

C.C. Roy, G. Delage, A. Fontaine, et al., The fecal microflora and bile acids in children with cystic fibrosis, American Journal of Clinical Nutrition 32 (1979) 2404–2409.
DOI Google Scholar
[59]

E.A. Grice, J.A. Segre, The skin microbiome, Nature Reviews Microbiology 9 (2011) 244–253.
DOI Google Scholar
[60]

H. Redel, Z. Gao, H. Li, et al., Quantitation and composition of cutaneous microbiota in diabetic and nondiabetic men, Journal of Infectious Diseases 207 (2013) 1105–1114.
DOI Google Scholar
[61]

S.E. Gardner, S.L. Hillis, K. Heilmann, et al., The neuropathic diabetic foot ulcer microbiome is associated with clinical factors, Diabetes 62 (2013) 923–930.
DOI Google Scholar
[62]

K. Akter, E.A. Lanza, S.A. Martin, et al., Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? British Journal of Clinical Pharmacology 71 (2011) 365–376.
DOI Google Scholar
[63]

N.T. Vagelatos, G.D. Eslick, Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship, Epidemiologic Reviews (2013) (in press).
DOI Google Scholar
[64]

A. Vignini, A. Giulietti, L. Nanetti, et al., Alzheimer’s disease and diabetes: new insights and unifying therapies, Current Diabetes Reviews 9 (2013) 218–227.
DOI Google Scholar
[65]

S.M. de la Monte, J.R. Wands, Alzheimer’s disease is type 3 diabetes-evidence reviewed, Journal of Diabetes Science and Technology 2 (2008) 1101–1113.
DOI Google Scholar
[66]

S. Karri, V. Acosta-Martinez, G. Coimbatore, Effect of dihydrotestosterone on gastrointestinal tract of male Alzheimer’s disease transgenic mice, Indian Journal of Experimental Biology 48 (2010) 453–465.
Google Scholar
[67]

P.E. Bendheim, B. Poeggeler, E. Neria, et al., Development of indole-3-propionic acid (OXIGON) for Alzheimer’s disease, Journal of Molecular Neuroscience 19 (2002) 213–217.
DOI Google Scholar
[68]

B. Kuhn, H. Hilpert, J. Benz, et al., Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists, Bioorganic & Medicinal Chemistry Letters 16 (2006) 4016–4020.
DOI Google Scholar
[69]

W.R. Wikoff, A.T. Anfora, J. Liu, et al., Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites, Proceedings of the National Academy of Sciences of the United States of America 106 (2009) 3698–3703.
DOI Google Scholar
[70]

A. Limon, J.M. Reyes-Ruiz, R. Miledi, Loss of functional GABA(A) receptors in the Alzheimer diseased brain, Proceedings of the National Academy of Sciences of the United States of America 109 (2012) 10071–10076.
DOI Google Scholar
[71]

J.A. Bravo, P. Forsythe, M.V. Chew, et al., Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve[J], Proceedings of the National Academy of Sciences of the United States of America 108 (2011) 16050–16055.
DOI Google Scholar
[72]

S.Y. Nowlin, M.J. Hammer, G. D’Eramo Melkus, Diet, inflammation, and glycemic control in type 2 diabetes: an integrative review of the literature, Journal of Nutrition and Metabolism 2012 (2012) 542698.
DOI Google Scholar
[73]

M.J. Fowler, Diabetes treatment. Part 2: Oral agents for glycemic management, Clinical Diabetes 25 (2007) 131–134.
DOI Google Scholar
[74]

X. Zhang, Y. Zhao, M. Zhang, et al., Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats, PLoS One 7 (2012) e42529.
DOI Google Scholar
[75]

H.Y. Wang, L.W. Qi, C.Z. Wang, et al., Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides, American Journal of Chinese Medicine 39 (2011) 1103–1115.
DOI Google Scholar
[76]

H. Bischoff, Pharmacology of alpha-glucosidase inhibition, European Journal of Clinical Investigation 24 (1994) 3–10.
DOI Google Scholar
[77]

A. Crozier, I.B. Jaganath, M.N. Clifford, Dietary phenolics: chemistry, bio-availability and effects on health, Natural Product Reports 26 (2009) 1001–1043.
DOI Google Scholar
[78]

C. Bisbal, K. Lambert, A. Avignon, Antioxidants and glucose metabolism disorders, Current Opinion in Clinical Nutrition & Metabolic Care 13 (2010) 439–446.
DOI Google Scholar
[79]

K. Hanhineva, R. Törrönen, I. Bondia-Pons, et al., Impact of dietary polyphenols on carbohydrate metabolism, International Journal of Molecular Sciences 11 (2010) 1365–1402.
DOI Google Scholar
[80]

M.I. Queipo-Ortuño, M. Boto-Ordóñez, M. Murri, et al., Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers, American Journal of Clinical Nutrition 95 (2012) 1323–1334.
DOI Google Scholar
[81]

L. Calani, M. Dall’Asta, E. Derlindati, et al., Colonic metabolism of polyphenols from coffee, green tea, and hazelnut skins, Journal of Clinical Gastroenterology 46 (2012) 95–99.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 10 June 2013
Revised: 30 August 2013
Accepted: 23 September 2013
Published: 11 October 2013
Issue date: December 2013

Copyright

© 2013 Beijing Academy of Food Sciences.

Acknowledgements

Acknowledgements

This research was supported by the National Natural Science Foundation of China (No. 31025019), the Innovation Team Development of the Ministry of Education of China (Grant No. IRT0967).

Rights and permissions

Return